argenx’s Post

📽️ Introducing Argent BioPharma’s Vision for the Future 📽️ We’re excited to share our journey in transforming healthcare through innovation. Our focus on addressing CNS conditions and immunology is driven by our commitment to advancing treatments for unmet medical needs. Watch the video to learn more about our vision and innovative approach!💡 #argentbiopharma #innovation #development

🎉 Thank you to everyone who joined our LIVE virtual discussion on Systems Immunology! In case you missed it, or want to watch it again, here's the link to the recording: https://lnkd.in/gw-dWv3n Don't forget, you can also review our April webinar! Stay tuned for more upcoming events from PLMI! #PLMI #predictivemedicine #systemsimmunology #freeevent #integrativemedicine #integrativehealth #functionalmedicine

As the International Myeloma Society (IMS) 2024 annual meeting kicks off in Rio de Janeiro, Brazil, Pharmacy Times will be providing comprehensive coverage of the conference, focusing on the latest advancements in myeloma research and diving into crucial areas like precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more. For a preview of some key interviews at the conference, check out the article below, and stay updated with more exclusive articles and expert interviews by visiting pharmacytimes.com. Link to article: [Don't Miss These Key Interviews and Data at the International Myeloma Society 2024 Congress](https://lnkd.in/ebny934K)

Missed the webinar? Check out the recording here: https://lnkd.in/gBTNF_9t Between live and fixed sample processing on our 25 marker spectral flow panel, we found (across 36 phenotypic populations, and 62 state marker subtypes): * 0.97 correlation of population frequencies * 0.91 correlation of state marker-positive subset frequencies Who cares? Immunotherapy developers struggling with the 10-20% failure rate for fresh specimens on trials. Big wins here: 1. Most obviously, ~10-20X reduction of failure rate through centralization of flow analysis. No need for a flow lab in every geography. Reduce variability by having all samples processed by the same facility. 2. Prospectively batch samples on spectral flow: You can store fixed samples until a whole set (for example all timepoints of an individual patient) is complete. 3. Reduce your committed processing cost and expand your analysis window. If you don't know upfront which samples to analyze, store your samples at -80C until you’re ready to decide.

September is #BloodCancerAwarenessMonth 1.27 million people globally are diagnosed with blood cancer each year. In Belgium, it’s around 7500 new diagnosis per year (*Belgian Cancer register, 2021 report). This highlights the urgent need for advancements in research and treatments. Join us in raising awareness and supporting this resilient community in September and all year long. Watch Dominique Tonelli M.D., Head of Medical Affairs Europe, Australia & Canada at Kite Pharma, a Gilead Sciences company, share thoughts about how all stakeholders at EU-level should collaborate to ensure we can bring the promise of #CellTherapy to those impacted by certain types of blood cancers. #innovation #EU #GeneralPharmaceuticalLegislation #ATMPs #BloodCancerAwarenessMonth

Read this new article in the European Journal of Immunology referencing our renowned QuickSwitch™ Custom Tetramer Kits! https://hubs.li/Q02vRTw70 Learn more about QuickSwitch™: https://hubs.li/Q02vRTWr0

How fitting that J.P. Morgan, the American banking tycoon who was so synonymous with monopolies that the monopoly-like term “Morganization” entered the financial lexicon, is the name of eponymous the Healthcare Conference that takes place in San Francisco between January 8-11.   This is because the main strategy of smaller companies at the conference is generally to try to “monopolize” the attention of the larger ones.   Fortunately, as a well-capitalized company, EpicentRx has the financial wherewithal to partner only with those companies where the fit and the chemistry—both personally and molecularly—are right.   Our two lead molecules are RRx-001 (nibrozetone) and AdAPT-001. The FDA fast track awarded small molecule RRx-001 (nibrozetone) is in an ongoing Phase 3 trial for the treatment of small cell lung cancer (SCLC) with a platinum doublet and in soon-to-start Phase 2b trial to prevent or ameliorate the development of severe oral mucositis during the treatment of head and neck cancer.   The oncolytic adenovirus, AdAPT-001, which expresses a transforming growth factor beta (TGF-β) trap to neutralize the immunosuppressive cytokine, TGF-β, is in a Phase 2 trial for the treatment of sarcomas.   If you’d like to learn more, please reach out to us directly to schedule a meeting.

What does the future of Alzheimer’s disease diagnostics look like? Professor Henrik Zetterberg shares his perspectives and research on developing next-generation diagnostics for Alzheimer’s, article: https://lnkd.in/dYtUaCeq In the clip, Professor Zetterberg discusses quantitative dried plasma microsampling technology - with only a few drops of dried blood from a finger prick, it’s possible to measure all key blood biomarkers for Alzheimer’s disease, by using ultra-sensitive multiplex technology NULISA (Alamar Biosciences, Inc.). These dried blood samples provide results that align with traditional venous blood draws. These biomarkers are stable in room temperature for up to six months. This opens the door to democratizing Alzheimer’s diagnostics by enabling remote testing, even in areas far from labs.   Professor Zetterberg and his team has used Capitainer®B50 and been one of the first users, pre-launch, of our new device Capitainer®SEP10.

From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie

In this recap of two adjuvant-focused sessions, we provide readers with an overview of the current IO adjuvant landscape with Dr Alexander Eggermont, and a look into BioNTech SE adjuvant vaccine work, from the 2024 IO360º conference. Read the article here: https://lnkd.in/g_wRGjfS #immunotherapy #immunooncology #cancerresearch #IO360 #adjuvant